Your browser doesn't support javascript.
loading
PRMT2 promotes HIV-1 latency by preventing nucleolar exit and phase separation of Tat into the Super Elongation Complex.
Jin, Jiaxing; Bai, Hui; Yan, Han; Deng, Ting; Li, Tianyu; Xiao, Ruijing; Fan, Lina; Bai, Xue; Ning, Hanhan; Liu, Zhe; Zhang, Kai; Wu, Xudong; Liang, Kaiwei; Ma, Ping; Gao, Xin; Hu, Deqing.
Afiliação
  • Jin J; National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, State Key Laboratory of Experimental Hematology, Key Laborator
  • Bai H; National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, State Key Laboratory of Experimental Hematology, Key Laborator
  • Yan H; National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, State Key Laboratory of Experimental Hematology, Key Laborator
  • Deng T; Key Laboratory of Breast Cancer Prevention and Therapy of Ministry of Education, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, 300060, Tianjin, China.
  • Li T; Department of Pathophysiology, School of Basic Medical Sciences, Wuhan University, 430071, Wuhan, China.
  • Xiao R; Department of Pathophysiology, School of Basic Medical Sciences, Wuhan University, 430071, Wuhan, China.
  • Fan L; Department of Infectious Diseases, Tianjin Second People's Hospital, Nankai University, 300192, Tianjin, China.
  • Bai X; The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, School of Basic Medical Sciences, Tianjin Medical University, 300070, Tianjin, China.
  • Ning H; National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, State Key Laboratory of Experimental Hematology, Key Laborator
  • Liu Z; The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, School of Basic Medical Sciences, Tianjin Medical University, 300070, Tianjin, China.
  • Zhang K; The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, School of Basic Medical Sciences, Tianjin Medical University, 300070, Tianjin, China.
  • Wu X; The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, School of Basic Medical Sciences, Tianjin Medical University, 300070, Tianjin, China.
  • Liang K; Department of Pathophysiology, School of Basic Medical Sciences, Wuhan University, 430071, Wuhan, China.
  • Ma P; Department of Infectious Diseases, Tianjin Second People's Hospital, Nankai University, 300192, Tianjin, China. docmaping@outlook.com.
  • Gao X; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, 300020, Tianjin, China. gaoxin1@ih
  • Hu D; Tianjin Institutes of Health Science, 301600, Tianjin, China. gaoxin1@ihcams.ac.cn.
Nat Commun ; 14(1): 7274, 2023 11 10.
Article em En | MEDLINE | ID: mdl-37949879

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Infecções por HIV / HIV-1 Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Infecções por HIV / HIV-1 Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article